Radisens secures €4.5m Commission investment

Radisens Diagnostics, based at CIT’s Rubicon Centre, landed the grant from the commission’s Horizon 2020 Research and Innovation initiative to help develop a blood testing device that will provide instant diagnosis for chronic diseases.
Radisens will use the funds to integrate diabetes, cardiovascular and kidney function panels on to its Gemini near-patient platform, giving instant results from a fraction of a drop of blood — a development that chief executive Jerry O’Brien says will have a profound impact on patients’ lives.